演讲人：Wanli Smith 博士，Associate Professor，美国Johns Hopkins大学
题目：Identification of Lrrk2 GTP binding inhibitors for PD
时间：2016年11月30日（星期三）下午2:30-3:30
地点：新威尼斯v0008独墅湖校区403-3120会议室
主办单位：新威尼斯v0008
报告人简介：
Dr. Wanli Smith is an associate professor in the Department of Psychiatry at Johns Hopkins University School of Medicine and the director of the Cellular Neurobiology Laboratory. She received her M.D. in clinical medicine and M.S. in pharmacology at Xi’an Medical University, and her Ph.D. in biochemistry and molecular biology at the Beijing Institute of Pharmacology and Toxicology in China. She pursued post-doctoral work in cellular and molecular biology laboratories in the National Institute on Aging at the National Institute of Health and in the Department of Psychiatry, Division of Neurobiology, at Johns Hopkins. Her lab is currently directed towards understanding the molecular pathogenesis of neurodegenerative diseases and other disorders such as obesity. Her research goal is to elucidate the molecular signaling pathways of these disorders, to identify potential therapeutic targets and to develop novel therapeutics.
近两年Wanli Smith实验室发表的代表性文章：
1. Liu J, Li T, Thomas JM, Pei Z, Jiang H, Engelender S, Ross CA, *Smith WW. Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson’s disease models. Hum Mol Genet. 2016, 25(4):672-80
2. Yang D, Das S, Song L, Li T, Yan J and *Smith WW. LDN-73794 attenuated LRRK2-induced degeneration in a Drosophila Parkinson’s disease model. Advance in Parkinson’s disease. 2015, 4: 49-58
3. Li T, He X, Thomas JM, Yang D, Xue F and *Smith WW. A novel GTP-binding inhibitor, Fx2149 attenuated LRRK2 toxicity in Parkinson’s disease models. PLoS One. 2015, 10(3):e0122461.
4. Li T, Yang D, Zhong S, Thomas JM, Xue F, Liu J, Kong L, Voulalas P, Hassan HE, Park JS, MacKerell AD Jr, *Smith WW. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson’s disease cell and mouse models. Hum Mol Genet. 2014, 23(23):6212-22